Related Experiment Videos
[Effectiveness of phosphomycin and its combinations with amikacin and cefotaxime in experimental plague infection]
Abstract:
When administered intramuscularly in doses of 8 and 16 mg/mouse, phosphomycin was highly active in the treatment of albino mice with experimental plague infection (80-100-percent protection of the animals from death). Combinations of phosphomycin with cefotaxime in inefficient or not sufficiently efficient doses had a synergistic effect. When the albino mice were treated with combinations of phosphomycin and amikacin, the percentage of the survived animals significantly increased in comparison to that after the use of the antibiotics alone.
Insights
Phosphomycin demonstrates high efficacy against experimental plague in mice. Combining phosphomycin with cefotaxime or amikacin enhances treatment outcomes, showing synergistic or significantly increased survival rates.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Plague remains a significant public health concern, necessitating effective therapeutic strategies.
- Antibiotic resistance poses a challenge in treating bacterial infections like plague.
- Investigating novel or combined antibiotic therapies is crucial for combating infectious diseases.
Purpose:
- To evaluate the efficacy of phosphomycin as a monotherapy against experimental plague in a murine model.
- To assess the synergistic potential of combining phosphomycin with cefotaxime.
- To determine the impact of combining phosphomycin with amikacin on treatment outcomes for plague.
Summary:
- Intramuscular administration of phosphomycin at 8 and 16 mg/mouse provided 80-100% protection against experimental plague in albino mice.
- Combinations of phosphomycin with cefotaxime exhibited synergistic effects, even at sub-optimal doses.
- Co-administration of phosphomycin and amikacin significantly improved survival rates compared to individual antibiotic treatments.
Impact:
- This study highlights phosphomycin's potential as a viable treatment option for plague.
- Combination therapies involving phosphomycin may offer enhanced efficacy and overcome resistance mechanisms.
- Findings support further research into phosphomycin-based regimens for plague treatment and potentially other bacterial infections.